Monday, September 9, 2013

White Paper: Amgen’s $10.4bn Onyx acquisition secures long-term oncology prospects

Amgen is looking to enhance the oncology portfolio as they face challenges from their upcoming biosimilars in 2015.  The deal is worth $10.4 billion.  Kyprolis is a disease developed to treat myeloma and was approved by the USFDA and is looking to gain approval in Europe.

Our partners at DataMonitor have recently published the paper Amgen’s $10.4bn Onyx acquisition secures long-term oncology prospects where they further examine the acquisition and what it means for Amgen as a  company and their goal to expand their current portfolio.

Recent developments in the acquisition show that Onyx stakeholders aren't pleased with the purchase and are stating the company's buying price - $10.4 billion -  is under the value of the current company. According to Bloomberg, the agreement also contained provisions that won't allow the company to accept any offers from other parties.

1 comment:

Felix Matt said...

I think through a tender offer, Amgen intends to effect the transaction, which is subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions besides regulatory clearance.